Victor Mendonça, chair of the Generic Market Access Committee at Medicines for Europe, outlines why patient access to medicines is at risk due to intense price pressure and unprecedented inflation and proposes ways to tackle this. The COVID-19 pandemic and…
In Europe, patient access to Orphan Medicinal Products (OMP) for the treatment of rare diseases remains inequitable. With the common goal of ensuring broader and faster access to OMPs across…
Pierre Meulien, Executive Director- Innovative Health Initiative, presents the public-private joint undertaking that boasts a total budget of EUR 2.4 billion and aims to build on the work of the…
Pharma and biotech companies have demonstrated their commitment to diversity, equity and inclusion (DEI), particularly with respect to gender equality with more and more women in leadership positions. Insights from…
Victor Mendonça, chair of the Generic Market Access Committee at Medicines for Europe, outlines why patient access to medicines is at risk due to intense price pressure and unprecedented inflation and proposes ways to tackle this. The COVID-19 pandemic and the conflict in Ukraine have caused unprecedented challenges for Europe, among which the surge of inflation which has increased cost…
Victor Mendonça, chair of the Generic Market Access Committee at Medicines for Europe, outlines why patient access to medicines is at risk due to intense price pressure and unprecedented inflation…
When the COVID-19 pandemic struck in early 2020, Europe’s reliance on active pharmaceutical ingredient (API) and generic medicine suppliers outside of the continent was laid bare. In the face of…
Pfizer and MSD recently became the latest companies to have COVID-19 treatments authorised by either the US FDA or EMA. Their oral antiviral drugs joined several monoclonal antibodies and others…
Writing in the December edition of DIA’s Global Forum magazine, Thomas Kühler updates his August piece on the progress towards a unified HTA system in Europe and the objectives of the recently…
The Top Five countries in Europe ranked by amount spent on pharma R&D. While some of the continent’s largest and most developed nations are represented, other smaller countries are punching…
See our Cookie Privacy Policy Here